Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced degranulation. by Jian Hao (160736)

Increased miR200c decreases FAP-1 expression. by Sabarinathan Ramachandran (444500)

Inhibition of ERK 1/2 decreases GM-CSF- and IL-3-responsive Eo/B CFU, but not IL-5-responsive colonies. by Pia Reece (589971)

PP2A inhibition decreases ACS5 accumulation. by Kyle R. Skottke (223882)

Decreased splicing efficiency in DENV infected cells. by Federico A. De Maio (3091644)

“…<p>(A) Schematic representation of splicing analysis. …”

Overexpression of miR-132-3p inhibits the TGF-<i>β</i>1/Smad2/3 signaling pathway in TGF-<i>β</i>1 induced MET-5A cells. by Yangyang Yin (14323701)

Subjects:

Mitochondrial respiration of HL-1 cells exposed for 12 or 72h to LG, NG, HG or IHG. by Patrick Mordel (17020879)

Measurement of the MMP in HL-1 cells exposed for 12 or 72h to LG, NG, HG or IHG. by Patrick Mordel (17020879)

Klf5 expression is down-regulated in the ruptured human and experimental AAA. by Dong Ma (584680)

Subjects:

Selective downregulation of SR Ca²⁺ handling proteins and decreased SR Ca²⁺ uptake in TG mice hearts. by Mayilvahanan Shanmugam (691549)

“…For each atrial Ca²⁺ uptake experiment, atria from four mice were pooled. n = 4 for each group. The V_max of Ca²⁺ uptake was obtained at pCa 5.5.…”

RTA 408 Increases Expression of Nrf2 Target Genes and Decreases Expression of Inflammatory Mediators in RAW 264.7 Cells. by Brandon L. Probst (727964)

Down-regulation of pol III activity in hypoxia is not due to a decrease in the abundance of TFIIIB, TFIIIC or pol III subunits by Isabelle Ernens (13462)

Decreased hypotaurine levels within cells lacking the ADO gene in U251 cells. by Hong Tian (169626)

Pretreatment of β-cells with recombinant CXCL12 improves viability and induces a decrease in PARP-1 activity. by Nevena Grdović (394542)

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects: